LianBio is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of innovative therapies in Greater China. Founded in 2017 and headquartered in Cambridge, Massachusetts, LianBio operates with a dual-hub model that combines global research capabilities with a dedicated presence in Hangzhou. The company’s strategy centers on leveraging partnerships with established biotech and pharmaceutical developers to bring medicines for oncology, rare diseases and immunology to Chinese patients more efficiently than traditional market entry approaches.
Through a network of licensing and collaboration agreements, LianBio assembles a diversified pipeline of clinical-stage and approved products. Key programs include therapies for rare cholestatic liver diseases and targeted oncology agents, many of which have already received regulatory clearance or are in late-stage clinical trials. By assuming responsibility for regulatory filings, manufacturing scale-up and local marketing, LianBio aims to shorten the pathway from global clinical proof-of-concept to patient access in China.
The company’s geographic focus encompasses mainland China, Hong Kong and Macau, leveraging relationships with local regulatory authorities and healthcare providers. LianBio’s Hangzhou site serves as its regional operations center, housing teams dedicated to clinical operations, regulatory affairs and commercial launch planning. This localized infrastructure is complemented by its U.S. headquarters, which supports global business development, corporate governance and high-level scientific collaboration.
Under the leadership of Chief Executive Officer Christopher Schaber, LianBio has grown its executive team to include seasoned professionals in drug development, regulatory strategy and commercial execution. The board and senior management draw on extensive industry experience, with backgrounds in multinational pharmaceutical firms and specialty biotech companies. As LianBio advances its existing portfolio and adds new collaborations, it aims to address unmet medical needs and deliver value for patients, partners and shareholders in one of the world’s fastest-growing biopharma markets.
AI Generated. May Contain Errors.
